The Release Trial: a randomised controlled trial of umbilical vein oxytocin versus placebo for the treatment of retained placenta

Abstract
Hypothesis Intraumbilical injection of oxytocin reduces the incidence of manual removal compared with placebo in the treatment of retained placenta. Entry criteria The women recruited will be stable haemodynamically, not bleeding vaginally, over 34 weeks of gestation and with a retained placenta for at least 30 minutes. Treatment arms Oxytocin (50 IU) or sterile water (in identical vials) in 25 mL saline injected through an intraumbilical venous catheter. Sample size Five hundred seventy‐two women. Primary endpoint Need for manual removal of placenta. Centres Initially, there will be two study sites in the UK (Liverpool and Sheffield) and five in Uganda (Mulago, Nsambia, Mengo, Rubaga and Arua). Funding World Health Organization and WellBeing of Women.

This publication has 0 references indexed in Scilit: